2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Transcatheter edge-to-edge repair for tricuspid valve regurgitation in apolipoprotein A-I–associated cardiac amyloidosis: case report

      case-report

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Amyloidosis is defined by abnormal protein folding and subsequent deposition in tissues. Cardiac involvement is usually related to misfolded monoclonal immunoglobulin light chains or misfolded transthyretin; however, apolipoprotein A-1–associated amyloidosis is a hereditary form of amyloidosis resulting from mutations in the AAPOA1 gene that can also result in cardiac amyloidosis. Although there have been advancements in noninvasive algorithms for the diagnosis of cardiac amyloidosis, endomyocardial biopsy (EMB) may still be warranted. All individuals undergoing EMB are susceptible to complications, including tricuspid valve injury resulting in severe tricuspid valve regurgitation.

          Case summary

          Our patient is a 70-year-old white man presented with symptoms of dyspnoea on exertion and decreased functional capacity, diagnosed previously with apolipoprotein A-I cardiac amyloidosis, confirmed by EMB. He developed progressive right-sided heart failure secondary to iatrogenic flail tricuspid leaflet related to the diagnostic EMB. He underwent a successful transcatheter tricuspid valve edge-to-edge repair with 4D intracardiac echocardiographic guidance. At the recent follow-up, the patient showed improved symptoms, with increased stamina, and transoesophageal echocardiography revealed a 65% ejection fraction and mild tricuspid regurgitation (TR).

          Discussion

          Tricuspid valve injury is one of the complications associated with EMB, which can result in severe TR. Transcatheter tricuspid valve edge-to-edge repair can be a useful option for patients considered too high risk for surgical intervention, such as those with advanced cardiac amyloidosis.

          Related collections

          Most cited references14

          • Record: found
          • Abstract: found
          • Article: not found

          Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases

          Cardiac amyloidosis is a serious and progressive infiltrative disease that is caused by the deposition of amyloid fibrils at the cardiac level. It can be due to rare genetic variants in the hereditary forms or as a consequence of acquired conditions. Thanks to advances in imaging techniques and the possibility of achieving a non-invasive diagnosis, we now know that cardiac amyloidosis is a more frequent disease than traditionally considered. In this position paper the Working Group on Myocardial and Pericardial Disease proposes an invasive and non-invasive definition of cardiac amyloidosis, addresses clinical scenarios and situations to suspect the condition and proposes a diagnostic algorithm to aid diagnosis. Furthermore, we also review how to monitor and treat cardiac amyloidosis, in an attempt to bridge the gap between the latest advances in the field and clinical practice.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found

            Systemic amyloidosis.

            Tissue deposition of protein fibrils causes a group of rare diseases called systemic amyloidoses. This Seminar focuses on changes in their epidemiology, the current approach to diagnosis, and advances in treatment. Systemic light chain (AL) amyloidosis is the most common of these conditions, but wild-type transthyretin cardiac amyloidosis (ATTRwt) is increasingly being diagnosed. Typing of amyloid fibrils, a critical determinant of therapy, has improved with the wide availability of laser capture and mass spectrometry from fixed histological tissue sections. Specific and accurate evaluation of cardiac amyloidosis is now possible using cardiac magnetic resonance imaging and cardiac repurposing of bone scintigraphy tracers. Survival in AL amyloidosis has improved markedly as novel chemotherapy agents have become available, but challenges remain in advanced disease. Early diagnosis, a key to better outcomes, still remains elusive. Broadening the amyloid-specific therapeutic landscape to include RNA inhibitors, fibril formation stabilisers and inhibitors, and immunotherapeutic targeting of amyloid deposits holds promise to transform outcomes in systemic amyloidoses.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Transcatheter Edge-to-Edge Repair for Treatment of Tricuspid Regurgitation

              Tricuspid regurgitation (TR) is a frequent disease with a progressive increase in mortality as disease severity increases. Transcatheter therapies for treatment of TR may offer a safe and effective alternative to surgery in this high-risk population.
                Bookmark

                Author and article information

                Contributors
                Role: Handling Editor
                Role: Editor
                Role: Editor
                Role: Editor
                Role: Editor
                Journal
                Eur Heart J Case Rep
                Eur Heart J Case Rep
                ehjcr
                European Heart Journal: Case Reports
                Oxford University Press (US )
                2514-2119
                December 2023
                30 November 2023
                30 November 2023
                : 7
                : 12
                : ytad582
                Affiliations
                Department of Cardiothoracic Surgery, Mayo Clinic , Jacksonville, FL, USA
                Department of Cardiovascular Disease, Mayo Clinic , Jacksonville, FL, USA
                Department of Cardiovascular Disease, Mayo Clinic , Jacksonville, FL, USA
                Department of Cardiovascular Disease, Mayo Clinic , Jacksonville, FL, USA
                Division of Advanced Heart Failure and Transplant Cardiology, Department of Transplantation, Mayo Clinic , 4500 San Pablo Road, Jacksonville, FL 32224, USA
                Author notes
                Corresponding author. Tel: +1 904 953 0859, Email: Lyle.melissa@ 123456mayo.edu

                Conflict of interest: None declared.

                Author information
                https://orcid.org/0000-0003-3330-7239
                https://orcid.org/0000-0002-5671-5596
                Article
                ytad582
                10.1093/ehjcr/ytad582
                10733207
                38130865
                b8137427-a022-4ad3-b5e6-3f3529f32c54
                © The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology.

                This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

                History
                : 08 March 2023
                : 08 November 2023
                : 16 November 2023
                : 20 December 2023
                Page count
                Pages: 4
                Categories
                Case Report
                Valvular Heart Disease
                AcademicSubjects/MED00200
                Ehjcr/14
                Ehjcr/1
                Ehjcr/36

                amyloidosis,tricuspid regurgitation,right heart failure,mitraclip,case report

                Comments

                Comment on this article